GoAI
Get started
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc.

SPRB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$51.58

−$0.405 · -0.78%

Aug 21, 4:00 PM ET

SPRB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

44

Fair Value

Momentum

23

Weakening

Sentiment

63

Bullish

Risk resilience

12

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Javier Szwarcberg
Listed since
Oct 9, 2020
Employees
22

Market position

Day range

Current $51.58

52-week range

Current $51.58

Open
$52.61
Previous close
$51.985
Volume
62.31K
0.91× average
Average volume
68.16K
Average daily volume
Market cap
141.96M USD
Beta
3.34
Market reference 1
50-day average
$48.6129
+6.10% above average
200-day average
$66.2986
-22.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
18.61M USD
P/E (TTM)
-1.26×
P/B (TTM)
1.5×
P/S (TTM)
0×
EV / EBITDA
-0.48×
Earnings yield
-58.35%
Free cash flow yield
-49.91%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-91.65%
Return on assets
-73.49%
Return on invested capital
-84.42%

Financial health

Debt / equity
0.09×
Current ratio
5.17×
Altman Z-score
-0.41
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends224%-273%-770%-1268%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Operating margin, FY2023: -515.34%Operating margin, FY2024: -1143.37%Net margin, FY2023: -474.96%Net margin, FY2024: -1079.94%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Operating margin FY2023 -515.34%. Operating margin FY2024 -1143.37%. Net margin FY2023 -474.96%. Net margin FY2024 -1079.94%.

Income trends

Revenue

4.91M USD-51.32%

Operating income

−36.51M USD+34.97%

Net income

−38.97M USD+26.53%
Income trends across reported periods16.71M USD−9.78M USD−36.28M USD−62.78M USDRevenue, FY2023: 10.09M USDRevenue, FY2024: 4.91M USDOperating income, FY2021: −42.07M USDOperating income, FY2022: −47.28M USDOperating income, FY2023: −51.99M USDOperating income, FY2024: −56.15M USDOperating income, FY2025: −36.51M USDNet income, FY2021: −42.29M USDNet income, FY2022: −46.18M USDNet income, FY2023: −47.92M USDNet income, FY2024: −53.04M USDNet income, FY2025: −38.97M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 10.09M USD. Revenue FY2024 4.91M USD. Operating income FY2021 −42.07M USD. Operating income FY2022 −47.28M USD. Operating income FY2023 −51.99M USD. Operating income FY2024 −56.15M USD. Operating income FY2025 −36.51M USD. Net income FY2021 −42.29M USD. Net income FY2022 −46.18M USD. Net income FY2023 −47.92M USD. Net income FY2024 −53.04M USD. Net income FY2025 −38.97M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—4.91M USD10.09M USD——
Gross profit—4.91M USD10.09M USD——
Research and development19.52M USD46.42M USD49.43M USD35.2M USD30.7M USD
Selling, general, and administrative16.99M USD14.64M USD12.65M USD12.09M USD11.37M USD
Operating expenses36.51M USD61.06M USD62.08M USD47.28M USD42.07M USD
Interest income1.14M USD3.42M USD4.56M USD1.52M USD119K USD
Interest expense90K USD307K USD483K USD420K USD345K USD
Depreciation and amortization21K USD46K USD70K USD74K USD68K USD
Operating income−36.51M USD−56.15M USD−51.99M USD−47.28M USD−42.07M USD
Net income−38.97M USD−53.04M USD−47.92M USD−46.18M USD−42.29M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-2949.04%
11 comparable reports
Latest EPS result
-6.68
Estimate -5.79 · Miss by 15.37%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.2-15.52-30.83-46.15Q2 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 15, 2025: actual -42.75, estimate -0.24, surprise -17712.05%, Miss. Q2 2025, reported May 6, 2025: actual -24, estimate -18.8, surprise -27.66%, Miss. Q3 2025, reported Aug 15, 2025: actual -3.5, estimate -18, surprise +80.56%, Beat. Q4 2025, reported Nov 10, 2025: actual -14.58, estimate -15.56, surprise +6.30%, Beat. Q1 2026, reported Mar 9, 2026: actual -9.58, estimate -12.87, surprise +25.56%, Beat. Q2 2026, reported May 13, 2026: actual -8.94, estimate -7.32, surprise -22.13%, Miss. Q3 2026, reported Aug 12, 2026: actual -6.68, estimate -5.79, surprise -15.37%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -5.82, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates53.98M36.06M18.14M212.5KQ3 '24BeatQ4 '24MissQ2 '25MissQ2 '25EstimateQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ4 '26Estimate
Q3 2024, reported Aug 12, 2024: actual 1.61M USD, estimate 1.5M USD, surprise +7.69%, Beat. Q4 2024, reported Nov 11, 2024: actual 602K USD, estimate 1.49M USD, surprise -59.70%, Miss. Q2 2025, reported Apr 15, 2025: actual 700K USD, estimate 885K USD, surprise -20.90%, Miss. Q2 2025, reported May 6, 2025: actual —, estimate 250K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 15, 2025: actual —, estimate 500K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 10, 2025: actual —, estimate 500K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 9, 2026: actual —, estimate 500K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 9, 2026: actual —, estimate 50M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$131.33

154.61% upside
Past 12 months12-month forecastHigh $150Average $131.33Low $104

Rating distribution

11 ratings
Strong buy00%
Buy764%
Hold436%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions
Ladenburg ThalmanndowngradeBuyNeutral

SPRB news

gurufocus.com

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord

Read source
businesswire.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with…

Read source
businesswire.com

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with…

Read source
businesswire.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies…

Read source
businesswire.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies…

Read source
businesswire.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 5, 2025

1:75

SPRB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SPRB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.64M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.52M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.37M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
915.98K
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
652.6K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
480.45K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
339.51K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
195K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research SPRB

research.disclaimer